Stem Cell Therapeutics (SSS)

[janetcanada]

What did happen in the morning was so very much DISHONEST!!!
Disgusting what "GREED" makes some peoples do !!!

From Stock House, from a respected poster rjc:

Thanks for the following AGM note from CSv2 at http://www.stockhouse.com/Bullboards/MessageDetail.aspx?p=0&m=28259940&l=0&r=0&s=SSS&t=LIST

and for the note from yesoilers at

http://www.stockhouse.com/Bullboards/MessageDetail.aspx?p=0&m=28260525&l=0&r=0&s=SSS&t=LIST

that I have found since I got home (hope I didn’t miss anybody) I’ll build on those.



Alan gave the normal investor presentation to us that covers already published information. I’ll comment on a couple of things from the presentation.



Alan gave the presentation based on his investor presentation slide set. Slide 6 showed what today’s share price antics messed up … his “surprise” AGM announcement that we would be getting the Trial results next Tuesday. He had to get that information out earlier today to help explain that the price action had nothing to do with a leak of any sort.



He explained that the particular rule that limited the Trial enrollment in India (that had previously been presented as a guideline) was that 25% of the Trial participation had to come from outside of India. What we ended up with was 93 patients enrolled in India and 3 patients enrolled in Canada.



There was a brief mention that the selling price of the NTx-265 (hCG + EPO) product was still up in the air, with a suggestion that $45,000 for the treatment was in line with current pharmaceutical pricing practices. In earlier company valuation estimates, Alan had been using a very conservative $3,000 for the treatment. Feel free to pick your own number at this point for budgeting. The eventual pricing responsibility will likely be in the hands of a future partner. In an earlier company presentation, the stroke market had been estimated at $1 billion for North America, and $1.5 billion for the world (per year). These numbers had been based on $3,000 per treatment.



Some stuff that we had already seen was shown again on Traumatic Brain Injury (TBI), and that was the rat data. One part of the story here was that TBI was much more severe a problem to fix, generally, than was stroke (and had no “standard of care” at all. In this pre-clinical Trial, the rats were subjected to brain impact while they were sedated. A functional scale (0 to 12) was used to measure function where 0 to 2 represented degrees of normal, and 12 represented dead. Over the first 2 days, the rats moved from a score of 2, to a new score of 10 or 11. At day 21, the score of the treated rats had moved back to 2 … where they started. Pretty impressive. The rat stroke results turned out to be predictive of human response. We’ll soon find out if the rat TBI results are also predictive of human response in the upcoming 10 patient initial Trial with human TBI patients (with the same treatment being used as in the stroke Trial).



Our Phase III stroke protocol will be based on what we learn from the Phase II stroke results. The end of Phase II meeting with the FDA will be held in H2 … July or later. An “end of Phase II” meeting is conducted to discuss (with the FDA) what an acceptable Phase III protocol would look like.



All of the SCT personnel there seemed to be proud of where they were at in the development program. In addition to Alan, I spoke to Jackie who looks after Intellectual Property, Barry who does finance, Allen who looks after the clinical programs, and a couple of other board members.



rjc